Opportunistic Infections Clinical Trial
Official title:
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities Using International Pharmacovigilance Database
NCT number | NCT05349383 |
Other study ID # | CSU20220499 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 22, 2022 |
Est. completion date | June 1, 2022 |
Verified date | June 2022 |
Source | Central South University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Although antibody-drug conjugate(ADC) has proved effective in treating many cancers, few patients receiving ADC may experience rare but life-threatening sepsis-related toxicities such as sepsis and septic shock. Today, data about sepsis/septic shock are scarce. The objective was to investigate reports of sepsis/septic shock adverse events related to ADC, including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin using international pharmacovigilance databases such as the FDA Adverse Event Reporting System (FAERS).
Status | Completed |
Enrollment | 24618 |
Est. completion date | June 1, 2022 |
Est. primary completion date | May 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Case reported in the FDA Adverse Event Reporting System (FAERS) or other international pharmacovigilance database of individual safety case reports to 12/31/2022 Adverse event reported were included the report with MedDRA terms: Sepsis(SMQ), agranulocytosis(SMQ), Opportunistic infections (SMQ). Patients treated with ADC included: Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin. Other cancer patients received common drug therapies such as chemotherapy, targeted therapy or immunotherapy would also be included as a comparator. Exclusion Criteria: Chronology not compatible between ADC and adverse event (sepsis-related toxicities) |
Country | Name | City | State |
---|---|---|---|
China | Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sepsis-related toxicity of antibody-drug conjugate. | Identification and report of the sepsis-related toxicity of ADC. The research includes the report with MedDRA terms: Sepsis(SMQ), agranulocytosis(SMQ), Opportunistic infections (SMQ). Drugs investigated are ADC: Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin. | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 | |
Secondary | Causality assessment of reported cardiovascular events according to the WHO system | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 | ||
Secondary | Description of the type of sepsis-related toxicities depending on the category of ADC | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 | ||
Secondary | Description of the drug-drug interactions associated with sepsis-related adverse events | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 | ||
Secondary | Description of the population of patients having a sepsis-related adverse events | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 | ||
Secondary | Description of the pathologies (cancer) for which the incriminated drugs have been prescribed | Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02454569 -
Vicente Ferrer HIV Cohort Study
|
||
Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT02982902 -
T Cell Therapy of Opportunistic Cytomegalovirus Infection
|
Early Phase 1 | |
Not yet recruiting |
NCT01541631 -
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
|
N/A | |
Completed |
NCT03087890 -
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
|
Phase 4 | |
Active, not recruiting |
NCT00814827 -
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
|
||
Completed |
NCT01557803 -
Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
|
N/A | |
Recruiting |
NCT03798301 -
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
|
Phase 1 | |
Completed |
NCT00137657 -
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
|
Phase 4 | |
Active, not recruiting |
NCT05694546 -
Re-engagement at Discharge 2
|
N/A | |
Recruiting |
NCT02337595 -
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03083756 -
Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients
|
N/A | |
Completed |
NCT00001477 -
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
|
N/A |